Table 4.
The percentage of cell population in each phase of cell cycle resulted from PSS, PL, and cisplatin treatment in 4 breast cancer cell lines
| Breast cancer cell line | Cell cycle phase (Mean (%) ± SE) | ||
|---|---|---|---|
| G0/G1 | S | G2/M | |
| MCF7 | |||
| - Untreated | 73.02 ± 5.30 | 15.68 ± 1.53 | 8.90 ± 3.86 |
| - PSS | 74.94 ± 3.65 | 9.13 ± 1.55 * | 13.94 ± 2.61 |
| - PL | 73.27 ± 4.32 | 7.27 ± 1.50 ** | 16.32 ± 3.97 |
| - Cisplatin | 58.56 ± 7.39 | 12.00 ± 2.93 | 28.06 ± 6.34 * |
| T47D | |||
| - Untreated | 77.15 ± 2.00 | 9.07 ± 1.07 | 13.24 ± 1.34 |
| - PSS | 75.99 ± 0.68 | 8.76 ± 1.05 | 14.64 ± 0.94 |
| - PL | 83.14 ± 1.60 * | 8.55 ± 0.98 | 7.98 ± 2.16 |
| - Cisplatin | 44.47 ± 15.48 | 2.57 ± 0.43 **** | 52.54 ± 15.06 * |
| MDA-MB-231 | |||
| - Untreated | 74.91 ± 1.22 | 9.34 ± 0.33 | 11.08 ± 3.02 |
| - PSS | 76.29 ± 1.92 | 3.73 ± 1.58 * | 12.07 ± 3.63 |
| - PL | 70.87 ± 3.19 | 7.83 ± 0.77 | 14.48 ± 1.90 |
| - Cisplatin | 90.12 ± 1.39 *** | 5.43 ± 1.97 | 2.82 ± 0.25 * |
| MDA-MB-468 | |||
| - Untreated | 80.64 ± 2.70 | 8.19 ± 1.23 | 9.95 ± 1.54 |
| - PSS | 79.83 ± 4.90 | 7.38 ± 2.81 | 11.16 ± 1.62 |
| - PL | 78.33 ± 5.28 | 8.63 ± 1.93 | 8.67 ± 2.74 |
| - Cisplatin | 79.62 ± 4.30 | 8.03 ± 1.37 | 9.25 ± 1.75 |
*, **, ***, **** represented P ≤ 0.05, P ≤ 0.01, P ≤ 0.001, and P ≤ 0.0001 from statistical analysis using Unpaired t-test